Chong Kun Dang issued a public notice on the 1st that it will discontinue the Phase III trial on its CKD-314 (Nafabeltan Inj.) it had been developing as a COVID-19 treatment.

Chong Kun Dang explained, “We found it difficult to conduct a clinical trial to identify the patients’ rate of progression to severe disease due to the reduced incidence of COVID-19 and the majority receiving inoculation in Korea. Therefore, in consideration of expert opinion and the comprehensive situation, we decided to discontinue the trial.”

Chong Kun Dang started the development of the COVID-19 treatment in earnest after receiving approval for its Phase 2 trial protocol on Nafabeltan in July 2020. The trial